Trial
NCT04892264
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Mayo Clinic
Collaborators
—
Condition
Plasma Cell Myeloma
Intervention
Belantamab Mafodotin
Why stopped
Low/slow accrual - did not proceed to Phase 2
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-18